Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.

Lee KH, Kim MK, Hyun MS, Kim JY, Park KU, Song HS, Lee SA, Lee WS, Bae SH, Ryoo HM, Cho YY.

J Opioid Manag. 2012 Jul-Aug;8(4):243-52. doi: 10.5055/jom.2012.0122. Erratum in: J Opioid Manag. 2012 Sep-Oct;8(5):336. J Opioid Manag. 2013 Mar-Apr;9(2):156.

PMID:
22941852
4.

Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).

Wallace M, Skowronski R, Khanna S, Tudor IC, Thipphawong J.

Curr Med Res Opin. 2007 May;23(5):981-9.

PMID:
17519065
5.

Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.

Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr, Dornseif BE, Damask MC.

J Pain Symptom Manage. 2002 May;23(5):355-68.

PMID:
12007754
6.
7.

A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.

Han HS, Lee KH, Lee KH, Ryu JS, Kim YC, Park SW, Oh HS, Park KT, Kwon JH, Lee PB, Lee WS, Kim YS, Ahn JB, Jeon SW, Lee SY, Seol YM, Kang JH, Yuh YJ, Oh SY, Kim SR, Ahn JS.

Support Care Cancer. 2014 Mar;22(3):741-50. doi: 10.1007/s00520-013-2030-1. Epub 2013 Nov 8.

PMID:
24203087
8.

A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.

Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R.

Pain Pract. 2010 Sep-Oct;10(5):404-15. doi: 10.1111/j.1533-2500.2009.00342.x.

PMID:
20384968
9.

Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.

Richarz U, Waechter S, Sabatowski R, Szczepanski L, Binsfeld H.

Pain Pract. 2013 Jan;13(1):30-40. doi: 10.1111/j.1533-2500.2012.00553.x. Epub 2012 Apr 18.

PMID:
22510252
10.

Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.

Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, Thipphawong J.

J Opioid Manag. 2009 Mar-Apr;5(2):97-105.

PMID:
19507806
11.

Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.

Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC.

J Int Med Res. 2008 Mar-Apr;36(2):343-52.

PMID:
18380946
12.

Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.

Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC.

Int J Clin Pract. 2007 Oct;61(10):1671-6.

13.
14.

Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.

Nalamachu S, Ruck D, Nalamasu R, Fasbinder S, Bansal R.

J Opioid Manag. 2013 Jan-Feb;9(1):43-9. doi: 10.5055/jom.2013.0146.

PMID:
23709303
15.

Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.

Nalamachu SR, Kutch M, Hale ME.

J Pain Symptom Manage. 2012 Dec;44(6):852-65. doi: 10.1016/j.jpainsymman.2011.12.280. Epub 2012 Jul 11.

PMID:
22795050
19.

Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.

Hale ME, Wallace MS, Taylor DR, Kutch M, Nalamachu S.

J Opioid Manag. 2012 Sep-Oct;8(5):299-314. doi: 10.5055/jom.2012.0130.

PMID:
23247907
20.

Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

Silvestri B, Bandieri E, Del Prete S, Ianniello GP, Micheletto G, Dambrosio M, Sabbatini G, Endrizzi L, Marra A, Aitini E, Calorio A, Garetto F, Nastasi G, Piantedosi F, Sidoti V, Spanu P.

Clin Drug Investig. 2008;28(7):399-407.

PMID:
18544000
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk